- The company’s highly experienced and successful pharmaceutical industry leadership team includes former senior executives from Novartis, GSK, and Bristol-Myers Squibb
- The team has executed eight clinical trials, including a seven-country, 12,400-participant Phase 3 trial of a prior influenza candidate, and built, owns, and operates its GMP biologics manufacturing facility
- BiondVax has an exclusive collaboration with the prestigious Max Planck Institute for Multidisciplinary Sciences (“MPG”) and the University Medical Center Göttingen (“UMG”), to develop a pipeline of innovative nanosized antibody therapies
- BiondVax’s experience, assets, and pipeline represent a rare opportunity for a company of its size
BiondVax Pharmaceuticals (NASDAQ: BVXV), a Jerusalem-based biotechnology company, is laser focused on developing, manufacturing, and commercializing innovative NanoAb immunotherapeutic products, primarily for treating infectious and autoimmune diseases. Collaborating with the prestigious Max Planck Institute for Multidisciplinary Sciences and the University Medical Center Göttingen (“UMG”), both in Germany, BiondVax is developing a pipeline of nanosized antibody (NanoAb) therapies addressing diseases underserved by current treatments and with large and growing markets, such as COVID-19, asthma and psoriasis.
NanoAbs, also known as nanobodies and VHH-antibodies, are alpaca-derived nanosized antibodies that exhibit multiple significant competitive advantages over existing antibody therapies, including stability at high temperatures, superior binding affinity, more effective and convenient routes of…
NOTE TO INVESTORS: The latest news and updates relating to BVXV are available in the company’s newsroom at https://ibn.fm/BVXV
BioMedWire (BMW) is a bio-med news and content distribution company that provides (1) access to a network of wire services via InvestorWire to reach all target markets, industries and demographics in the most effective manner possible, (2) article and editorial syndication to 5,000+ news outlets (3), enhanced press release services to ensure maximum impact, (4) social media distribution via the Investor Brand Network (IBN) to millions of social media followers, (5) a full array of corporate communications solutions, and (6) a total news coverage solution with BMW Prime. As a multifaceted organization with an extensive team of contributing journalists and writers, BMW is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. By cutting through the overload of information in today’s market, BMW brings its clients unparalleled visibility, recognition and brand awareness. BMW is where news, content and information converge.
To receive SMS text alerts from BioMedWire, text “Biotech” to 844-397-5787 (U.S. Mobile Phones Only)
For more information, please visit https://www.biomedwire.com
BioMedWire is part of the InvestorBrandNetwork.